KCCQ is a validated instrument to self assess quality of life including physical function and social function. NYHA relates symptoms to every day activities and patients quality of life. MLWHF is a validated instrument to self assess how heart failure and its treatment affect the key physical, emotional, social and psychological dimensions of quality of life. Additional surgery after the initial implant operation.
Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Inclusion Criteria: The following are general criteria; more specific conditions are included in the study protocol: Listed for cardiac transplantation NYHA Class IV heart failure symptoms On inotropic support, if tolerated Despite medical therapy, the patient must meet hemodynamic criteria for cardiogenic shock Exclusion Criteria: The following are general criteria; more specific conditions are included in the study protocol: Evidence of, or risk factors for end-organ dysfunction that would make LVAS implantation futile Existence of factors that would adversely affect patient survival or function of the LVAS.
Intolerance to anticoagulant or antiplatelet therapies. Existence of any ongoing mechanical circulatory support other than intra-aortic balloon counterpulsation. Participation in any other clinical investigation that is likely to confound study results or affect study outcome. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials. More Information. Use of a continuous-flow device in patients awaiting heart transplantation.
N Engl J Med. Incidence, risk, and consequences of atrial arrhythmias in patients with continuous-flow left ventricular assist devices. J Card Surg. Epub Apr Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Epub Nov Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device.
J Am Coll Cardiol. Heart-assist devices. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Not Applicable. Study Type :. Interventional Clinical Trial.
Actual Enrollment :. Study Start Date :. Actual Primary Completion Date :. Actual Study Completion Date :. Washington, District of Columbia, United States, Unfortunately, there aren't enough hearts for every person in need: The median wait time for a heart transplant, according to data from the U.
Department of Health and Human Services , is just shy of a year. Some people don't live long enough while waiting for a transplant, and some are too sick to make it on the transplant list at all. They need a solution that's built to last.
When the technology was first designed in , it was powered by a large, external machine, and it was only designed to work for a few hours. Even in the s, researchers considered the device an interim option. But evidence hinted that the LVAD could have a longer shelf life.
But LVADs weren't just a prelude. In , the U. Food and Drug Administration FDA approved HeartMate II for destination therapy, making it the first such device authorized to provide permanent support for heart failure patients.
More than a decade after the device was introduced, more than 26, people have received the HeartMate II. The first recipients are now celebrating more than 10 years of active, normal life with the pump.
And their devices don't show any signs of stopping. Thanks to the device's endurance, the HeartMate series has become a destination therapy, not just a bridge-to-transplant therapy. That distinction has made the LVAD available to more people than just those awaiting a transplant — it can help those who are ineligible to receive a donor heart resume their daily lives.
At about half the size of the HeartMate II, the HeartMate 3 offers the same long-lasting hardiness, but it's enhanced by a more advanced system. For Tyrone Morris , who lives with congestive heart failure and hopes to one day receive a new heart, the HeartMate 3 serves an important purpose: It lets him live his daily life free of heart failure symptoms.
LVAD in place and spirits high, he's gotten back to doing what he loves — bowling and running a barbecue restaurant in Milwaukee, Wis. Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size. Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site.
Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
0コメント